Harnessing aging to transform health
Obesity and other metabolic diseases are among the most prevalent and pressing health challenges of our time.
Age is a critical risk factor.
We are harnessing the biology of human aging to develop new therapies for metabolic diseases
We are harnessing the biology of human aging to develop new therapies for metabolic diseases
We are harnessing the biology of human aging to develop new therapies for metabolic diseases
Find out more
Azelaprag for obesity
Our lead program, azelaprag, has potential to be a first and best-in-class oral weight loss therapy co-administered with incretin drugs to achieve injectable-like total weight loss.
Discovery platform
Our human-first discovery platform analyzes proprietary multi-omics data captured over decades to identify the molecular mediators of aging and disease.
Our pipeline programs target key pathways that drive metabolic aging based on novel insights from our platform.
Recent Press Releases
November 4, 2024
